BALA CYNWYD, Pa., July 17, 2012 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of Human Genome
Sciences, Inc. ("Human Genome" or the "Company") (Nasdaq- HGSI)
relating to the proposed acquisition by GlaxoSmithKline plc.
("GSK").
Under the terms of the transaction, Human Genome shareholders
will receive only $14.25 in cash for
each of Human Genome stock they own. The investigation concerns
possible breaches of fiduciary duty and other violations of state
law by the Board of Directors of Human Genome for not acting in the
Company's shareholders' best interests in connection with the sale
process to GSK. The transaction may undervalue the Company as Human
Genome stock traded at $29.60 a share
on April 28, 2011 and traded at
$14.59 a share as recently as
April 26, 2012. In addition, an
analyst has set a price target on Human Genome stock at
$23.00 per share and sales of Human
Genome's new lupus drug BENLYSTA reached $31.2 million for the first quarter of 2012.
If you own shares of Human Genome stock and wish to discuss the
legal ramifications of the proposed transaction, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith,
LLC, Two Bala Plaza, Suite 602, Bala
Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/453-hgsi-human-genome-sciences-inc.html,
or by calling toll free 877-LEGAL-90.
SOURCE Brodsky & Smith, LLC